Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion

Breast Cancer Research

Volumn 14, Issue 5, 2012, Pages

  Aceto, Nicola ^a   Duss, Stephan ^a   MacDonald, Gwen ^a   Meyer, Dominique S ^a,b   Roloff, Tim C ^a   Hynes, Nancy E ^a   Bentires Alj, Mohamed ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; NEU DIFFERENTIATION FACTOR;

ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; AUTOCRINE EFFECT; BIOLOGICAL MODEL; BREAST TUMOR; CANCER GRADING; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENETICS; INFORMATION PROCESSING; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DATASETS AS TOPIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-8; MODELS, BIOLOGICAL; NEOPLASM GRADING; NEUREGULIN-1; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84867297810     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3329     Document Type: Article

References (33)

1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21:177-184. 10.1016/j.ceb.2008.12.010, 19208461.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
4. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
5. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Embo J 1995, 14:4267-4275. 394510, 7556068.
6. Carraway KL, Soltoff SP, Diamonti AJ, Cantley LC. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 1995, 270:7111-7116. 10.1074/jbc.270.13.7111, 7535767.
7. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223. 10.1007/s10911-008-9083-7, 18454306.
8. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10:1813-1821.
9. Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat 2011, 132:463-470.
10. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887. 10.1158/0008-5472.CAN-08-0380, 18632642.
11. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
12. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441. 10.1038/nature05474, 3025857, 17206155.
13. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
14. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N, Harris LN, Richardson A, Neel BG, Gu H. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 2006, 12:114-121. 10.1038/nm1341, 16369543.
15. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One 2011, 6:e17911. 10.1371/journal.pone.0017911, 3061871, 21445301.
16. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
17. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
18. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012, 18:529-537. 10.1038/nm.2645, 22388088.
19. Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. Chem Immunol 1992, 51:236-265.
20. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391. 10.1016/S1359-6101(01)00016-8, 11544106.
21. Green AR, Green VL, White MC, Speirs V. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 1997, 72:937-941. 10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q, 9378554.
22. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
23. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010, 120:485-497. 10.1172/JCI39397, 2810075, 20051626.
24. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res 2011, 17:6125-6129. 10.1158/1078-0432.CCR-10-2743, 3312242, 21685479.
25. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994, 29:423-429. 10.1007/BF02361238, 7951851.
26. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998, 152:93-100. 1858127, 9422527.
27. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999, 189:546-551. 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L, 10629556.
28. Singh RK, Varney ML, Bucana CD, Johansson SL. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999, 9:383-387. 10.1097/00008390-199908000-00007, 10504057.
29. Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, Brannstrom M. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?. Gynecol Oncol 1998, 71:420-423. 10.1006/gyno.1998.5198, 9887242.
30. Radke J, Schmidt D, Bohme M, Schmidt U, Weise W, Morenz J. -Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 1996, 56:83-87. [Article in German], 10.1055/s-2007-1022247, 8647364.
31. Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z, Li XC, Tang H, Abbruzzese JL, Xie K. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000, 20:935-946. 10.1089/10799900050198372, 11096450.
32. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998, 51:161-167.
33. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741. 10.1158/1078-0432.CCR-07-4843, 18980965.